All Posts: triple-negative breast cancer

• Biology Behind New Drug Used to Treat Triple-Negative Breast Cancer Uncovered

  How TTP488 (azeliragon), an experimental drug, impairs aggressive, triple-negative breast cancer from metastasizing has been uncovered at the cellular level, according to researchers at Georgetown University’s Lombardi Comprehensive Cancer Center.

  Category: News Release Tags: breast cancer, breast cancer research, cancer, cancer research, clinical trials, triple-negative breast cancer

• Clinical Trial Result Leads to New Treatment Option for Hard-to-Treat Breast Cancer

  (June 4, 2021) — A clinical trial exploring a new treatment for breast cancer found that women with a hard-to-treat form of the disease lived longer without the disease coming back following treatment. The trial was conducted at sites around the world, including Georgetown Lombardi Comprehensive Cancer Center. “This finding represents a significant step forward […]

  Category: Lombardi Stories Tags: breast cancer, cancer, clinical trials, triple-negative breast cancer

• Glynda’s Story: A Chance to Advance Treatment for Aggressive Cancer

  (January 11, 2021) — Inspired by the kindness, proficiency and dedication of her health care team at Georgetown Lombardi Comprehensive Cancer Center, Glynda Brown, a 52-year-old Maryland resident, felt determined to “pay it forward” and make a positive difference for future patients by participating in a clinical trial after she was diagnosed with triple-negative breast […]

  Category: Lombardi Stories Tags: breast cancer, cancer, cancer research, clinical trials, minority health, triple-negative breast cancer